Principal Investigator
Cynthia Levy
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20230701
Clinical Trial Summary
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
PBC (Primary Biliary Cholangitis)
Contact Information
Study Contact
Sonia Carvalho
Phone Number
+1 (305) 2434639
Email
scarvalho@miami.edu